DEF 14A: Virios Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals

Virios Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 18, 2024, featuring proposals for director elections and ratification of the company's independent accounting firm.

Summary

• Virios Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 18, 2024, at 11:00 a.m. Eastern Time.
• Stockholders of record as of April 23, 2024, are entitled to vote at the meeting.
• The meeting will address the election of six director nominees and the ratification of FORVIS, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR all director nominees and FOR the ratification of FORVIS, LLP.
• The company's common stock outstanding as of the record date was 19,257,937 shares.
• William L. Pridgen, M.D., will transition from his role as a Director to scientific advisory following the 2024 Annual Meeting.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions, reflecting a balanced and professional approach.

Positives

• The Board of Directors unanimously recommends voting FOR the election of all director nominees.
• The Board of Directors unanimously recommends voting FOR the proposal to ratify FORVIS, LLP as the independent registered public accounting firm.
• The virtual meeting format enables stockholders to attend and participate from any location at no cost, provides for cost savings to Virios Therapeutics, Inc. and our stockholders and reduces the environmental impact of our Annual Meeting.

Future Outlook

The proxy statement outlines the proposals to be voted on at the upcoming annual meeting, focusing on the election of directors and the ratification of the company's accounting firm, providing a framework for the company's governance and financial oversight for the coming year.

Management Comments

• Greg Duncan, Chairman and Chief Executive Officer: 'Thank you for your continued support of and ownership in our Company. We look forward to your participation at the meeting.'

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring shareholders have a voice in key decisions such as electing directors and ratifying the selection of an independent accounting firm. The virtual format reflects a growing trend towards accessibility and cost-effectiveness in shareholder meetings.

Comparison to Industry Standards

• Holding an annual meeting to elect directors and ratify the selection of an independent accounting firm is standard practice for publicly traded companies, such as Gilead Sciences (GILD) and CorMedix Inc. (CRMD).
• The use of a virtual meeting format aligns with the trend of increasing accessibility and cost-effectiveness, similar to practices adopted by other companies in the pharmaceutical and biotechnology sectors.
• The director independence criteria used by Virios Therapeutics are consistent with Nasdaq Stock Market Rules and SEC regulations, ensuring proper corporate governance.

Management Changes

Related Party Transactions

• The Company uses Gendreau Consulting, LLC, a consulting firm (Gendreau), for drug development, clinical trial design and planning, implementation and execution of contracted activities with clinical research organizations.
• Gendreaus managing member is the Companys Chief Medical Officer (CMO).
• The Company has and may continue to contract the services of the CMOs spouse through Gendreau to serve as the Companys Medical Director and to perform certain activities in connect with the Companys ongoing clinical development of product candidates.
• During the years ended December 31, 2023 and 2022, the Company paid Gendreau $103,624 and $356,088, respectively, and had accounts payable of $0 and $21,000 to Gendreau as of December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders have the opportunity to vote on key decisions regarding the company's leadership and financial oversight.
• Employees are indirectly affected by the decisions made at the Annual Meeting, as they influence the company's overall direction and stability.
• The outcome of the meeting can impact the company's relationships with its accounting firm and other service providers.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce the results of the votes following the Annual Meeting in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Virios Therapeutics, Stockholders, Director Election, FORVIS, LLP, Accounting Firm, Corporate Governance